T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Ardagh Metal Packaging
AMBP
$3.16B
| $337K | ﹤0.01% |
82,160
+8,344
| +11% | +$31.6K |
|
2577
Lexeo Therapeutics
LXEO
$407M
| $337K | ﹤0.01% |
33,872
+21,907
| +183% | +$200K |
|
2578
National Bankshares
NKSH
$272M
| $337K | ﹤0.01% |
10,027
| – | – |
|
2579
Titan Machinery
TITN
$420M
| $337K | ﹤0.01% |
22,364
+1,705
| +8% | +$27.4K |
|
2580
Ironwood Pharmaceuticals
IRWD
$674M
| $335K | ﹤0.01% |
99,363
+19,185
| +24% | +$49.8K |
|
2581
Barings BDC
BBDC
$987M
| $334K | ﹤0.01% |
36,293
+19
| +0.1% | +$168 |
|
2582
Five Star Bancorp
FSBC
$1.16B
| $334K | ﹤0.01% |
9,334
+1,049
| +13% | +$36.4K |
|
2583
Aldeyra Therapeutics
ALDX
$86.9M
| $333K | ﹤0.01% |
64,262
| – | – |
|
2584
TaskUs
TASK
$667M
| $333K | ﹤0.01% |
28,207
| – | – |
|
2585
i3 Verticals
IIIV
$325M
| $332K | ﹤0.01% |
13,150
+1,057
| +9% | +$29.8K |
|
2586
Republic Bancorp
RBCAA
$1.92B
| $332K | ﹤0.01% |
4,806
+411
| +9% | +$28.5K |
|
|
CTEV
2587
Claritev Corp
CTEV
$716M
| $332K | ﹤0.01% |
7,746
-2,800
| -27% | -$142K |
|
2588
RxSight
RXST
$292M
| $331K | ﹤0.01% |
31,756
-1,772
| -5% | -$17.8K |
|
|
KBDC
2589
Kayne Anderson BDC
KBDC
$909M
| $331K | ﹤0.01% |
+23,066
| New | +$336K |
|
|
CBLL
2590
CeriBell Inc
CBLL
$892M
| $331K | ﹤0.01% |
15,051
+2,008
| +15% | +$31.2K |
|
|
MCW
2591
DELISTED
Mister Car Wash
MCW
| $330K | ﹤0.01% |
59,274
+7,168
| +14% | +$37.7K |
|
2592
Vanguard Dividend Appreciation ETF
VIG
$115B
| $330K | ﹤0.01% |
1,500
-428
| -22% | -$93.5K |
|
2593
GCM Grosvenor
GCMG
$2.85B
| $329K | ﹤0.01% |
29,025
+2,789
| +11% | +$31.9K |
|
2594
FerroAtlántica
GSM
$818M
| $329K | ﹤0.01% |
70,707
+7,399
| +12% | +$34.2K |
|
2595
Xperi
XPER
$320M
| $329K | ﹤0.01% |
56,070
-7,485
| -12% | -$46.9K |
|
2596
McEwen Inc
MUX
$1.14B
| $327K | ﹤0.01% |
17,615
| – | – |
|
|
UDMY
2597
DELISTED
Udemy
UDMY
| $327K | ﹤0.01% |
55,775
+4,739
| +9% | +$27.6K |
|
2598
Fossil Group
FOSL
$330M
| $326K | ﹤0.01% |
86,628
| – | – |
|
2599
Lindblad Expeditions
LIND
$2.26B
| $325K | ﹤0.01% |
22,507
+2,506
| +13% | +$31.6K |
|
2600
ArriVent BioPharma
AVBP
$1.4B
| $325K | ﹤0.01% |
16,115
+1,760
| +12% | +$36.6K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.